Reeling from a hefty civil and criminal settlement, Avanir stumbles into PhIII Alzheimer's failure
Avanir’s no good, awful, simply terrible week came to a disastrous end last Friday as the Otsuka subsidiary was forced to report that its second Phase III trial for a new-and-improved version of its commercial drug had failed in treating Alzheimer’s dementia — likely scuttling any future it may have had in the most difficult of all diseases.
The news came one day after Avanir agreed to pay $116 million in civil and criminal payments and enter into a deferred adjudication agreement revolving around whistleblower claims that company reps had paid doctors to prescribe Nuedexta in nursing homes as a way to control dementia patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.